Voyager Therapeutics (NASDAQ:VYGR) Stock Crosses Below 50 Day Moving Average – Here’s What Happened

Voyager Therapeutics, Inc. (NASDAQ:VYGR) shares passed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $3.08 and traded as low as $2.25. Voyager Therapeutics shares last traded at $2.27, with a volume of 967,005 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on VYGR shares. HC Wainwright restated a “buy” rating on shares of Voyager Therapeutics in a research note on Thursday, August 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Voyager Therapeutics in a report on Friday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $16.50.

Voyager Therapeutics Stock Down 6.5%

The firm’s fifty day moving average price is $3.04 and its 200-day moving average price is $3.44.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Thursday, August 6th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.08. Voyager Therapeutics had a negative return on equity of 57.92% and a negative net margin of 312.63%. The firm had revenue of $3.17 million for the quarter, compared to analysts’ expectations of $4.52 million. On average, analysts anticipate that Voyager Therapeutics, Inc. will post -1.63 EPS for the current fiscal year.

Hedge Funds Weigh In On Voyager Therapeutics

Hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new stake in shares of Voyager Therapeutics in the 2nd quarter worth $18,102,000. EcoR1 Capital LLC boosted its stake in Voyager Therapeutics by 497.2% during the fourth quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company’s stock valued at $15,731,000 after buying an additional 3,332,544 shares in the last quarter. Altshuler Shaham Ltd bought a new position in Voyager Therapeutics during the fourth quarter valued at about $801,000. Renaissance Technologies LLC boosted its stake in Voyager Therapeutics by 95.0% during the first quarter. Renaissance Technologies LLC now owns 578,024 shares of the company’s stock valued at $2,231,000 after buying an additional 281,574 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in Voyager Therapeutics during the second quarter worth about $122,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a biotechnology company focused on developing gene therapies for neurological diseases. The company uses its proprietary TRACER capsid discovery platform to identify adeno-associated virus (AAV) capsids designed to improve the delivery of genetic medicines to the brain and central nervous system.

Voyager’s research and development programs have addressed conditions including Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis and Friedreich’s ataxia.